Clinical Trial Update: A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement [Phase 2]

View source ↗

Summary

Phase 2 study evaluating 5 μg/kg Tbo-filgrastim in infants, children, and adolescents with solid tumors without bone marrow involvement has completed; results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia
• Solid Tumor

Drugs mentioned

• Tbo-filgrastim (tbo-filgrastim)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Neutropenia | Phase 2 | Status: COMPLETED | Results posted: 2018-07-31